Clinical Trial Update: Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of FTY720 (fingolimod) in de novo adult renal transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• FTY720 (fingolimod) (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 2 | Status: COMPLETED